Beike Publishes New Research on Wharton’s Jelly-derived Mesenchymal Stem Cells in Acute Myocardial Infarction
On July 15th of 2015, Beike Biotechnology Co., Ltd. alongside leading Chinese hospitals and universities published new research utilizing Wharton’s Jelly derived mesenchymal stem cells as a safe and effective…
Through strategic licensing, acquisition and independent R&D, Beike Biotechnology has gained a strategic position in the immunotherapy field. Beike has multiple international cutting-edge and innovative immunotherapy technologies and products becoming…
Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions
Beike Biotechnology, the world’s largest stem cell provider, has begun the production of ‘high-dose’ umbilical cord derived mesenchymal stem cell packets containing no less than 50 million cells per pack….
ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company
RANCHO CORDOVA, Calif., Feb. 10, 2011 /PRNewswire/ — ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it…
The Three Pillars of Cell Therapy
The quest for the fountain of youth has been prevalent throughout history. Thus, it is unsurprising that current research is being undertaken to understand the process of aging and to…
Taizhou City, Jiangsu Province, China August 8, 2014 / PRNewswire / – In recent years, with the rapid development of stem cell biology, immunology, molecular techniques, tissue engineering and other…